“The vaccine will include at least three different variants of the S-protein - Wuhan, “delta” and “omicron”, and, in principle, as a result of vaccination, antibodies of three different specificities should be produced and protect against all possible variants of “omicron”, he said.
Earlier, Gunzburg noted that the coronavirus vaccine containing virus-like particles does not contain live virus.
He also clarified that the new drug will be two-component.
On February 16, the Russian Ministry of Health approved the conduct of phases I-II clinical trials of a coronavirus vaccine containing virus-like particles.
The study will be carried out by the Center.
Gamaleya with the participation of volunteers aged 18 to 55 "to assess the tolerability, safety and immunogenicity of the medicinal product."